Clearside Biomedical, Inc.
CLSDQOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7M | $8.2M | $1.3M | $29.6M | $7.9M | $2.2M |
| Operating income | −$28.9M | −$24.8M | −$30.3M | −$627,000 | −$17.9M | −$30.3M |
| Net income | −$34.4M | −$32.5M | −$32.9M | $376,000 | −$18.2M | −$30.8M |
| Total assets | $25.1M | $34.0M | $51.3M | $42.9M | $19.3M | $26.8M |
| Total liabilities | $64.0M | $49.9M | $40.7M | $4.9M | $10.6M | $15.6M |
| Equity | −$38.9M | −$15.9M | $10.6M | $38.0M | $8.8M | $11.2M |
| EPS (diluted) | $-0.47 | $-0.53 | $-0.55 | $0.01 | $-0.39 | $-0.81 |
| Shares out. | 74.7M | 61.4M | 60.1M | 57.4M | 44.9M | 36.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −1735.7%
- Net margin
- −2064.4%
- Return on equity
- 88.4%
- Return on assets
- −136.7%
- Return on capital (ROCE)
- −142.1%
- Liabilities / assets
- 254.6%
- Debt / equity
- —
- Book value / share
- $-0.52
- Revenue growth (YoY)
- −79.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -50.16distress
- Accruals / assets
- −38.4%clean
- Beneish M-Score
- -1.96normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 107,196 | 23.1 | -3.1% |
| Apr 30, 2026 | 110,633 | 1.6 | +32.8% |
| Apr 15, 2026 | 83,291 | 1.4 | 0.0% |
| Mar 31, 2026 | 83,291 | 1.3 | +2.3% |
| Mar 13, 2026 | 81,392 | 4.6 | +7.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Other material eventDec 29, 2025
- Delisting / listing-standard noticeDec 8, 2025
- Bankruptcy or receivership · Delisting / listing-standard notice · Regulation FD disclosureNov 25, 2025
- Other material eventOct 7, 2025
- Amended charter or bylawsSep 11, 2025
- Amended charter or bylawsSep 11, 2025
- Entered a material agreementSep 8, 2025
- Delisting / listing-standard notice · Shareholder voteSep 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.